<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03711058</url>
  </required_header>
  <id_info>
    <org_study_id>J1887</org_study_id>
    <secondary_id>IRB00175864</secondary_id>
    <secondary_id>CA209-8LC</secondary_id>
    <nct_id>NCT03711058</nct_id>
  </id_info>
  <brief_title>Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer</brief_title>
  <official_title>A Phase I/II Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase I/II study of PI3Kinase inhibition (copanlisib) and anti-PD-1 antibody nivolumab in
      relapsed/refractory solid tumors with expansions in mismatch-repair proficient (MSS)
      colorectal cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 10, 2019</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine maximum tolerated dose (MTD) of copanlisib with fixed dose nivolumab</measure>
    <time_frame>2 years</time_frame>
    <description>Number of patients having a dose limiting toxicities (DLT) at each level.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>6-month objective response rate (ORR) of patients treated with copanlisib and nivolumab</measure>
    <time_frame>6-months</time_frame>
    <description>The proportion of subjects with partial response (PR) or complete response (CR) as defined by Response Evaluation Criteria in Solid Tumors (RECIST 1.1)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR) status at 6 months.</measure>
    <time_frame>6-months</time_frame>
    <description>Percentage of participants achieving stable disease (SD) or better (SD + partial response (PR) + (CR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) status at 6 months.</measure>
    <time_frame>6-months</time_frame>
    <description>Number of months from the first documentation of a response to date of disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) status at 6 months.</measure>
    <time_frame>6-months</time_frame>
    <description>Number of months from treatment to disease progression (PD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) status at 6 months.</measure>
    <time_frame>6-months</time_frame>
    <description>Number of months from the date of first treatment until death or end of follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants experiencing study drug-related toxicities</measure>
    <time_frame>2 years</time_frame>
    <description>Number of participants experiencing study drug-related adverse events Grade 3 or higher as defined by CTCAE v5.0.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor Along With Microsatellite Stable (MSS) Colon Cancer</condition>
  <condition>Colon Cancer</condition>
  <arm_group>
    <arm_group_label>Phase I - Copanlisib and Nivolumab (De-Escalation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II - Copanlisib and Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Copanlisib</intervention_name>
    <description>Copanlisib will be administered as a 60 minute IV infusion (-5min/+10min) at a dose of 45 mg - 60 mg IV. Copanlisib will be administered once a week (days 1, 8, and 15 or Day 1 and Day 15 of each 28 day cycle).
Drug: 45 or 60 mg IV</description>
    <arm_group_label>Phase I - Copanlisib and Nivolumab (De-Escalation)</arm_group_label>
    <arm_group_label>Phase II - Copanlisib and Nivolumab</arm_group_label>
    <other_name>Bay 80-6946</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab 480 mg will be administered as a 60 minute IV infusion (-5min/+10min) on Day 1 of each 28 day cycle.
Drug: 480 mg IV</description>
    <arm_group_label>Phase I - Copanlisib and Nivolumab (De-Escalation)</arm_group_label>
    <arm_group_label>Phase II - Copanlisib and Nivolumab</arm_group_label>
    <other_name>OPDIVO, Bay 80-6946</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age â‰¥18 years.

          -  Ability to understand and willingness to sign a written informed consent document.

          -  Have histologically metastatic or unresectable microsatellite stable (MSS) solid tumor
             cancer or microsatellite stable MSS colon cancer.

          -  Must have received all curative treatment options and at least 2 lines of systemic and
             standard therapy.

          -  Must have measurable disease based on RECIST 1.1

          -  Must have biopsiable disease.

          -  ECOG performance status 0 or 1

          -  Life expectancy of greater than 3 months.

          -  Patients must have adequate organ and marrow function defined by study-specified
             laboratory tests within 21 days of initial study drug.

          -  Men must use acceptable form of birth control while on study.

          -  Woman of childbearing potential must have a negative pregnancy test and follow
             contraceptive guidelines as defined per protocol.

        Exclusion Criteria:

          -  Prior treatment with immunotherapy agents (including, anti-PD-1, anti-PD-L1,
             anti-PD-L2, anti-CTLA4, etc.).

          -  Prior therapy with a P13K inhibitor

          -  Chemotherapy, radiotherapy, investigational therapy, or surgery within 4 weeks prior
             to first dose of treatment.

          -  Has received prior radiotherapy within 2 weeks prior to the start of treatment.

          -  Patient who is receiving or have received any other investigational agents within 4
             weeks prior to the first dose of treatment.

          -  Has received a live vaccine 30 days prior to the first dose of study drug.

          -  Has known progressive disease or active treatment.

          -  Has known central nervous system (CNS) metastases and/or carcinomatous meningitis.

          -  Has symptomatic ascites or has required a paracentesis in the last 12 weeks.

          -  Hypersensitivity reaction to study drug.

          -  Patients diagnosed of immunodeficiency or are on any immunosuppressive agents within 7
             days prior to first dose of study drug.

          -  Has active autoimmune disease that has required systemic treatment in the past 12
             months, or a documented history of clinically severe autoimmune disease, or a syndrome
             that requires systemic steroids or immunosuppressive agents.

          -  Has a history of (non-infectious) pneumonitis that required steroids or has current
             pneumonitis.

          -  Has an active infection requiring systemic therapy.

          -  Infection with HIV or hepatitis B or C.

          -  CMV PCR (cytomegalovirus polymerase chain reaction) positive.

          -  Known history or concurrent interstitial lung disease.

          -  HbA1c &gt;8.5% at screening.

          -  Patient with uncontrolled intercurrent illness including, but not limited to,
             uncontrolled infection, symptomatic congestive heart failure, unstable angina
             pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would
             limit compliance with study requirements.

          -  Use of anti-arrhythmic therapy (beta blockers or digoxin are permitted).

          -  Use of CYP3A4 inhibitors and inducers within 2 weeks of starting study drug and
             throughout treatment.

          -  Any arterial or venous thrombotic or embolic events.

          -  Non-healing wound, ulcer, or fracture.

          -  Patients with evidence or history of bleeding condition.

          -  Had a blood or platelet transfusion within 7 days of Cycle 1 Day 1 treatment.

          -  Seizure disorder requiring anti-seizure medication.

          -  Conditions, including alcohol or drug dependence, intercurrent illness, or lack of
             sufficient peripheral venous access, that would affect the patient's ability to comply
             with study visits and procedures.

          -  Are pregnant or breastfeeding.

          -  Unwilling or unable to follow the study schedule for any reason.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nilofer Azad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins Medical Institution</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susan Sartorius-Mergenthaler, RN</last_name>
    <phone>410-614-3644</phone>
    <email>Sartosu@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ellen Lilly-Foreman, RN</last_name>
    <phone>443-287-4961</phone>
    <email>lillyel@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Sartorius-Mergenthaler, RN</last_name>
      <phone>410-614-3644</phone>
      <email>Sartosu@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ellen Lilly-Foreman, RN</last_name>
      <phone>443-287-4961</phone>
      <email>lillyel@jhmi.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 15, 2018</study_first_submitted>
  <study_first_submitted_qc>October 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2018</study_first_posted>
  <last_update_submitted>July 10, 2020</last_update_submitted>
  <last_update_submitted_qc>July 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunotherapy</keyword>
  <keyword>Nivolumab</keyword>
  <keyword>Copanlisib</keyword>
  <keyword>Unresectable</keyword>
  <keyword>Metastatic</keyword>
  <keyword>PD-1</keyword>
  <keyword>P13K</keyword>
  <keyword>Antibody</keyword>
  <keyword>Solid Tumors</keyword>
  <keyword>Colon Cancer</keyword>
  <keyword>MSS</keyword>
  <keyword>Mismatch-repair proficient</keyword>
  <keyword>Microsatellite stable</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

